Womble Bond Dickinson Partner Chris Mammen will be a speaker at the American Conference Institute’s Life Sciences AI Summit. The summit, which takes place Feb. 21-22 in New York, will address legal, regulatory, and compliance issues for safe and responsible innovation in the biopharma and medical device/diagnostic industries.

Mammen will take part in a panel discussion on, “IP Protections and AI Inventions in the Life Sciences: Exploring Complexities in Inventorship and Ownership.” The panel will discuss such issues as:

  • Untangling AI’s impact on intellectual property in the life sciences industry; 
  • Evaluating IP protections when AI is utilized as part of the inventive/creative process;
  • Assessing infringement risks of existing IP when used for AI training, selection, or generation; and
  • Comparing the complexities of AI-generated inventions, data ownership, and copyright infringement.

Mammen will be joined in the conversation by Special Competitive Studies Project (SCSP) Senior Director Rama Elluru, Novartis VP/Global Head for IP Affairs Corey Salsberg, and Biotechnology Industry Organization (BIO) Deputy General Counsel/VP for Intellectual Property Hans Sauer.

Mammen is the Office Managing Partner of Womble Bond Dickinson's San Francisco office. He previously led the firm’s US Intellectual Property Litigation Group and serves on the firm’s Global Board. Chris co-founded the firm’s AI practice and is a member of its Innovation Board.